Dr. Patel Discusses Zanubrutinib in MCL

Video

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses zanubrutinib in the treatment of patients with mantle cell lymphoma.

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses zanubrutinib (BGB-3111) in the treatment of patients with mantle cell lymphoma (MCL).

At the 2018 ASH Annual Meeting, there was an oral presentation of the investigational BTK inhibitor zanubrutinib in patients with relapsed/refractory MCL who were treated in China. Overall, Patel says, response rates appeared to be quite high. In fact, the complete response rate (CRR) seen with zanubrutinib was reported at approximately 58%, which is slightly higher than the CRR seen with the FDA-approved BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence).

However, it is hard to compare zanubrutinib with the other BTK inhibitors because there have not yet been any head-to-head studies. With that being said, Patel notes that it will be interesting to see if this CRR advantage with zanubrutinib holds true in longer-term follow-up data. Patel adds that the toxicity profile of zanubrutinib also appeared to be favorable, with a low incidence of grade 3/4 toxicities and treatment discontinuation observed. Based on these findings, in January 2019, the FDA granted the inhibitor a breakthrough therapy designation for the treatment of adult patients with MCL who have received at least 1 prior therapy.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute